Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

SIS Buyback 2022 Record Date, Price & Ratio Details

By Jagat Joshi
October 10, 2022

SIS buyback 2022 was announced on June 29, 2022. The SIS buyback open date October 4. SIS Ltd buyback record date is August 30. The investor should buy the SIS Ltd shares before the record date to get eligibility for the buyback.

SIS Ltd Buyback of ₹80 crores approved by the board of directors at the meeting was held on June 29, 2022. SIS Ltd Buyback will be done via the Tender Offer route through the stock exchange mechanism. The board of directors of the company approved the buyback by the Company of its fully paid-up equity shares having a face value of ₹5 each equity share at a price not exceeding ₹550 per Equity Share and for an aggregate amount not exceeding ₹80 crores from the shareholders. Check out SIS Ltd Buyback 2022 details below:

SIS Ltd (formerly Security and Intelligence Services India) provides security, facility management, and cash logistics services, which are essential to the functioning of a vibrant and healthy economy. They have emerged as a trusted leader across these business segments in India and other geographies in the Asia Pacific region. SIS Group is one of the largest manpower security firms in the Indo-Pacific region. They offers Security, Cash Logistics, and Facility Management Services in India, Australia, and a few Asia-Pacific regions.

SIS Ltd Buyback 2022 Dates & Record Dates

Buyback Meeting Date:	June 29, 2022
Buyback Announcement Date:	June 29, 2022
Buyback Record Date:	August 30, 2022
Buyback Open Date:	October 4, 2022
Buyback Close Date:	October 18, 2022
Finalization of Buyback Acceptance:	October 28, 2022

SIS Ltd Buyback 2022 Offer Details

SIS Ltd buyback of 14,54,545 equity shares at a price of ₹550 per equity share. The buyback offers not to exceed ₹80 crores of the total buyback offer size.

Offer Amount:	₹80 Crores
Number of Shares:	14,54,545 Equity Shares
Face Value:	₹5 per equity share
Buyback Price:	₹550 per equity share
Listing:	BSE & NSE
Buyback Type:	Tender Offer
Letter of Offer:	Click Here

SIS Ltd Buyback 2022 Acceptance Ratio

The investor should buy around 363 shares at a current market price of ₹454 (as of June 29, 2022). The calculation will be ₹2,00,000 / ₹550 buyback price = 363 shares.

Acceptance Ratio	Investment	Shares Buyback	Profit
33%	₹165,090	120	₹11,520
50%	₹165,090	181	₹17,376
75%	₹165,090	272	₹26,112
100%	₹165,090	363	₹34,848

SIS Ltd Financial Report

₹ in Crores
Year	Revenue	Expense	PAT
2020	₹3041	₹2880	₹86.33
2021	₹3030	₹2903	₹57.09
2022	₹3381	₹3228	₹133.90

SIS Ltd Buyback 2022 Eligible Share Holders

The investors are eligible for the buyback scheme who have SIS Ltd shares in their Demat account as the [.]. Investors can participate in the SIS Ltd Buyback 2022 scheme as per the opening form by selling their shares. The payment will be given as per the accepted shares by the company under the SIS Ltd buyback scheme.

SIS Ltd Buyback 2022 Registrar

Link Intime India Pvt Ltd
C 101, 247 Park,
L.B.S. Marg, Vikhroli (West),
Mumbai 400083, Maharashtra
Tel: 022-49186270, 49186200
Email: rnt.helpdesk@linkintime.co.in
Website: http://www.linkintime.co.in

SIS Ltd Buyback 2022 Lead Managers

Edelweiss Financial Services Ltd

SIS Ltd Company Address

SIS Ltd
Annapoorna Bhawan,
Telephone Exchange Road, Kurji,
Patna, Bihar – 800010
Tel: 0612-2266666
Email: investorrelations@sisindia.com
Website: http://www.sisindia.com

How to Apply the SIS Buyback through Zerodha?

Log in to Console in Zerodha Website or in Application. Go to Portfolio and Click on Corporate Actions. You will see the Company Name “SIS”. Click on Place Order. Enter your Quantity and submit SIS Buyback Application Form.

How to Apply the SIS Buyback through Upstox?

Log in to Upstox Application with your credentials. Select the Account Section. You will see the Company Name “SIS”. Click on SIS Stock for Buyback. Enter your Quantity and submit SIS Buyback Application Form.

How to Apply the SIS Buyback through Paytm Money?

Log in to Paytm Money Application with your credentials. Select the SIS. Enter your Quantity and submit SIS Buyback Application Form.

SIS Ltd Buyback 2022 FAQs

When is SIS Ltd Buyback 2022 Record Date?

SIS Ltd buyback 2022 record date is August 30, 2022.

When is SIS Ltd Buyback 2022 Open Date?

SIS Ltd buyback 2022 open date is October 4, 2022.

What is SIS Ltd Buyback 2022 Price?

The company has fixed the price at ₹550 per share.

How to apply for SIS Ltd Buyback 2022?

As per the record date you need to have SIS Ltd shares in your Demat account. You can participate in buyback after having the stock in your account.

Follow IPO Watch for the upcoming IPO news and their reviews, also keep following us on Twitter, Facebook, and Instagram. For our latest videos, subscribe to our YouTube channel.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.